Membrane Type 1 Matrix Metalloproteinase-associated Degradation of Tissue Inhibitor of Metalloproteinase 2 in Human Tumor Cell Lines*
暂无分享,去创建一个
J. Foidart | A. Noël | C. Munaut | A. Remacle | F. Frankenne | G. Murphy | E. Maquoi | E. Baramova | N. Sounni
[1] D. Fishman,et al. Ovarian carcinoma regulation of matrix metalloproteinase-2 and membrane type 1 matrix metalloproteinase through beta1 integrin. , 1999, Cancer research.
[2] P. Brown. Clinical studies with matrix metalloproteinase inhibitors , 1999, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[3] J. Keski‐Oja,et al. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. , 1998, The Biochemical journal.
[4] H. Sato,et al. Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells. , 1998, Journal of biochemistry.
[5] A. Gulino,et al. Tissue inhibitor of metalloproteinase-2 protection of matrix metalloproteinase-2 from degradation by plasmin is reversed by divalent cation chelator EDTA and the bisphosphonate alendronate. , 1998, Cancer research.
[6] Y. Okada,et al. TIMP-2 Promotes Activation of Progelatinase A by Membrane-type 1 Matrix Metalloproteinase Immobilized on Agarose Beads* , 1998, The Journal of Biological Chemistry.
[7] C. López-Otín,et al. Induction of matrix metalloproteinase activation cascades based on membrane-type 1 matrix metalloproteinase: associated activation of gelatinase A, gelatinase B and collagenase 3. , 1998, The Biochemical journal.
[8] J. Foidart,et al. Inhibition of matrix metalloproteinase 2 maturation and HT1080 invasiveness by a synthetic furin inhibitor , 1998, FEBS letters.
[9] M. Cilli,et al. TIMP‐2 over‐expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis , 1998 .
[10] Gillian Murphy,et al. The TIMP2 Membrane Type 1 Metalloproteinase “Receptor” Regulates the Concentration and Efficient Activation of Progelatinase A , 1998, The Journal of Biological Chemistry.
[11] Y. DeClerck,et al. Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) Binds to the Catalytic Domain of the Cell Surface Receptor, Membrane Type 1-Matrix Metalloproteinase 1 (MT1-MMP)* , 1998, The Journal of Biological Chemistry.
[12] M. d’Ortho,et al. MT1‐MMP on the cell surface causes focal degradation of gelatin films , 1998, FEBS letters.
[13] Z. Werb. ECM and Cell Surface Proteolysis: Regulating Cellular Ecology , 1997, Cell.
[14] W. T. Chen,et al. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[15] F. Blasi,et al. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes , 1997, The EMBO journal.
[16] J. Foidart,et al. Involvement of PA/plasmin system in the processing of pro‐MMP‐9 and in the second step of pro‐MMP‐2 activation , 1997, FEBS letters.
[17] H. Nagase. Activation mechanisms of matrix metalloproteinases. , 1997, Biological chemistry.
[18] A. Rehemtulla,et al. Membrane Type Matrix Metalloproteinase 1 Activates Pro-gelatinase A without Furin Cleavage of the N-terminal Domain* , 1996, The Journal of Biological Chemistry.
[19] H. Sato,et al. Activation of a recombinant membrane type 1‐matrix metalloproteinase (MT1‐MMP) by furin and its interaction with tissue inhibitor of metalloproteinases (TIMP)‐2 , 1996, FEBS letters.
[20] G. Butler,et al. The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation , 1996, The Journal of Biological Chemistry.
[21] M. Nakajima,et al. Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. , 1996, Cancer research.
[22] J. Westermarck,et al. Regulation of membrane-type matrix metalloproteinase-1 expression by growth factors and phorbol 12-myristate 13-acetate. , 1996, European journal of biochemistry.
[23] H. Shimada,et al. Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. , 1996, Cancer research.
[24] Y. Okada,et al. Cell surface binding and activation of gelatinase A induced by expression of membrane‐type‐1‐matrix metalloproteinase (MT1‐MMP) , 1996, FEBS letters.
[25] S. Weiss,et al. Transmembrane-deletion Mutants of the Membrane-type Matrix Metalloproteinase-1 Process Progelatinase A and Express Intrinsic Matrix-degrading Activity (*) , 1996, The Journal of Biological Chemistry.
[26] H. Sato,et al. MEMBRANE-TYPE MATRIX METALLOPROTEINASES , 2017 .
[27] S. Zucker,et al. Activation of human umbilical vein endothelial cell progelatinase A by phorbol myristate acetate: a protein kinase C-dependent mechanism involving a membrane-type matrix metalloproteinase. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[28] M. Seiki,et al. Intermolecular Autolytic Cleavage Can Contribute to the Activation of Progelatinase A by Cell Membranes (*) , 1995, The Journal of Biological Chemistry.
[29] A. Schwartz,et al. Receptor Cell Biology: Receptor-Mediated Endocytosis , 1995, Pediatric Research.
[30] R. Giavazzi,et al. Matrix metalloproteinase inhibition: a review of anti-tumour activity. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[31] W. Stetler-Stevenson,et al. gelatinase A/TIMP‐2 imbalance in lymph‐node‐positive breast carcinomas, as measured by RT‐PCR , 1995, International journal of cancer.
[32] J. Stevens,et al. Agonist-induced desensitization of dopamine D1 receptor-stimulated adenylyl cyclase activity is temporally and biochemically separated from D1 receptor internalization. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[33] A. Krantz,et al. Novel indolactam-based inhibitors of matrix metalloproteinases , 1995 .
[34] J. Foidart,et al. Cell surface binding of TIMP‐2 and pro‐MMP‐2/TIMP‐2 complex , 1995, FEBS letters.
[35] A. Strongin,et al. Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.
[36] W. Stetler-Stevenson,et al. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. , 1995, The EMBO journal.
[37] Hiroshi Sato,et al. The C-terminal Region of Membrane Type Matrix Metalloproteinase Is a Functional Transmembrane Domain Required for Pro-gelatinase A Activation (*) , 1995, The Journal of Biological Chemistry.
[38] Y. DeClerck,et al. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. , 1994, Cancer research.
[39] A. Shinagawa,et al. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). , 1994, Journal of cell science.
[40] Motoharu Seiki,et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells , 1994, Nature.
[41] L. Liotta,et al. Prognosis of gastric carcinoma revealed by interactions between tumor cells and basement membrane. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[42] M. J. Clague,et al. Vacuolar ATPase activity is required for endosomal carrier vesicle formation. , 1994, The Journal of biological chemistry.
[43] A. Strongin,et al. Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. , 1993, The Journal of biological chemistry.
[44] H. Shimada,et al. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. , 1992, Cancer research.
[45] K. Kato,et al. Bafilomycin A1 inhibits the targeting of lysosomal acid hydrolases in cultured hepatocytes. , 1991, Biochemical and biophysical research communications.
[46] L. Liotta,et al. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.
[47] M A Moses,et al. Identification of an inhibitor of neovascularization from cartilage. , 1990, Science.
[48] L. Liotta,et al. Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. , 1989, The Journal of biological chemistry.
[49] K. Altendorf,et al. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[50] J. Jensenius,et al. Eggs: conveniently packaged antibodies. Methods for purification of yolk IgG. , 1981, Journal of immunological methods.
[51] I. Pastan,et al. Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. , 1980, The Journal of biological chemistry.
[52] M. Fini,et al. Regulation of Matrix Metalloproteinase Gene Expression , 1998 .
[53] W. Stetler-Stevenson,et al. Molecular regulation of cellular invasion--role of gelatinase A and TIMP-2. , 1996, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[54] L. Liotta,et al. Cancer invasion and metastasis: positive and negative regulatory elements. , 1991, Cancer investigation.